NCT06188520 - A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

348

Participants

Timeline

Start Date

December 5, 2023

Primary Completion Date

June 17, 2026

Study Completion Date

June 17, 2026

Conditions

ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)

Interventions

DRUG

AZD8421

CDK2 inhibitor

DRUG

Camizestrant

SERD

DRUG

Ribociclib

CDK4/6 inhibitor

DRUG

Palbociclib

CDK4/6 inhibitor

DRUG

Abemaciclib

CDK4/6 inhibitor

Trial Locations (14)

3002

RECRUITING

Research Site, East Melbourne

8035

RECRUITING

Research Site, Barcelona

31005

RECRUITING

Research Site, Pamplona

37201

RECRUITING

Research Site, Nashville

46010

RECRUITING

Research Site, Valencia

63141

RECRUITING

Research Site, St Louis

77030

RECRUITING

Research Site, Houston

02903

RECRUITING

Research Site, Providence

03722

RECRUITING

Research Site, Seoul

06351

RECRUITING

Research Site, Seoul

CB2 0XY

RECRUITING

Research Site, Cambridge

LS9 7TF

RECRUITING

Research Site, Leeds

EC1A 7BE

RECRUITING

Research Site, London

M20 4BX

RECRUITING

Research Site, Manchester